Document:

EX-10.20

 EXHIBIT 10.20 

MARTIN MARIETTA MATERIALS, INC. 

FORM OF PERFORMANCE SHARE UNIT AWARD AGREEMENT 

THIS PERFORMANCE SHARE UNIT AWARD AGREEMENT, made as of
[                    ] (the “Award Agreement”), between Martin Marietta Materials, Inc., a North Carolina corporation (the
“Company”),                     (the “Employee”). 

 

	1.	GRANT 

 Pursuant to the Martin Marietta Materials, Inc. Amended and Restated Stock-Based
Award Plan (the “Plan”), the Company hereby grants the Employee                     Performance Share Units (the
“Award”) as the target amount of a performance-based stock unit award on the terms and conditions contained in this Award Agreement, and subject to the terms and conditions of the Plan. Depending on the Company’s performance as
set forth in Section 4, the participant may earn zero percent (0%) to two hundred percent (200%) of the target number of Performance Share Units awarded. The term “Performance Share Unit” or “PSU(s)” as
used in this Award Agreement refers only to the Performance Share Units awarded to the Employee under this Award Agreement. 
  

	2.	GRANT DATE 

 The Grant Date is
[                    ]. 
  

	3.	MEASUREMENT PERIOD 

 Subject to the terms and conditions hereof and of the Plan, the
measurement period begins on [                    ] and ends on
[                    ] (the “Measurement Period”). Except as otherwise provided in this Award Agreement or the Plan, the PSUs will
become vested on December 31, 2016, at the end of the Measurement Period (the “Vesting Date”). 
  

	4.	PAYMENT OF PERFORMANCE SHARE UNITS 

  

	 	(a)	Vesting of Award. Unless forfeited or converted and paid earlier as provided in Section 7 below, the Performance Share Units granted hereunder will vest (“Vest” or
“Vesting”) and be converted into shares of Common Stock and delivered to the Employee as soon as practicable following the Vesting Date (but in no event later than 60 days following the Vesting Date) provided that the Employee is
employed by the Company on the Vesting Date. The Vesting and conversion from PSUs to Common Stock will be one PSU for one share of Common Stock. 

  

	 	(b)	Performance Goals. The performance goals that must be attained in order to satisfy the Vesting requirements subject to this Award (the “Performance Goals”) are as follows: Omitted for filing
purposes. 

  

	 	1)	[                    ] percent ([    ]%) of the Award will vest based on [Measure 1] during the
Measurement Period (“[        ]”); 

  

	 	2)	[                    ] percent ([    ]%) of the Award will vest based on [Measure 2] during the
Measurement Period (“[        ]”); and 

  
 1 

	 	3)	[                    ] percent ([    ]%) of the Award will vest based on [Measure 3] during the
Measurement Period (“[        ]”). 

  

	 	(c)	Percentage of Awards Payable. The percentage of the Award that Vests and will be paid with respect to the Measurement Period in connection with the PSUs is conditioned on the satisfaction of the performance goals
set forth in the table below, which have been established by the Committee (the “Percentage”). Omitted for filing purposes. 

  

																	
	 Percentage of Target PSUs That Vest
	 	 	50%	 	  	100%	 	  	200%	 
	 Measure
	  	Weight	 	 	Threshold	 	  	Target	 	  	Maximum	 
	 [Measure 1]
	  	 	[    	]% 	 	 	[        	] 	  	 	[        	] 	  	 	[        	] 
	 [Measure 2]
	  	 	[    	]% 	 	 	[        	] 	  	 	[        	] 	  	 	[        	] 
	 [Measure 3]
	  	 	[    	]% 	 	 	[        	] 	  	 	[        	] 	  	 	[        	] 

  

	 	(d)	Shares Payable. The number of PSUs payable is the target number awarded in this Award Agreement multiplied by the Percentage of Target PSUs that vest in the table above. Performance levels below threshold
performance result in a payout of zero for that portion, and performance levels above maximum performance result in a payout of 200% for that portion. For performance levels falling between the values as shown above, the Percentage will be
determined by interpolation. Payment will be made in Common Stock. 

  

	 	(e)	The Value of the Stock Issued as Payment for PSUs Earned. The basis of the Common Stock payable will be its fair market value (“Fair Market Value”) determined by the closing price as of the
most recent New York Stock Exchange close for the Common Stock on the business day that immediately precedes the date on which payment is made under this Award Agreement (the “Payment Date”). 

 

	 	(f)	Payment Determination. The Committee may exercise its discretion to reduce the payment under this Award Agreement to no more than the target level if the Company’s TSR for the Measurement Period is less than
zero (0). 

  

	 	(g)	Non-Recurring Events. The Committee shall exclude from the performance results any non-recurring expenses or gains/losses, such as acquisition costs, unless, in the Committee’s discretion, it determines
otherwise. 

  

	5.	DIVIDEND EQUIVALENTS 

 On each date that dividends are paid (each a “Dividend
Payment Date”) on shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) with respect to which the record date (the “Record Date”) also occurs during the Restriction
Period, the Company will credit to an account for the Employee an amount equal to the dividend paid on a share of the Common Stock multiplied by the number of Performance Share Units. These dividend equivalent amounts shall be paid to the Employee
quarterly on each March 31, June 30, September 30 and December 31 during the Restriction Period; provided, however, that if any such date falls on a non-business day, such payment will be made on the business day
immediately prior to such date. Any remaining dividend equivalent amounts credited to the account of the Employee on the date that the 

  
 2 

 
Performance Share Units are converted to shares of Common Stock, or subsequently credited to such account with respect to a Record Date that occurs during the Restriction Period, shall be paid to
the Employee on the next successive Dividend Payment Date. The dividend equivalent amounts shall be paid from the general assets of the Company and shall be treated and reported as additional compensation for the year in which payment is made. 

 

	6.	TRANSFERABLE ONLY UPON DEATH 

 This Performance Share Unit grant shall not be assignable
or transferable by the Employee except by will or the laws of descent and distribution. 
  

	7.	TERMINATION, RETIREMENT, DISABILITY OR DEATH 

  

	 	(a)	Termination. If the Employee’s employment with the Company is terminated prior to the Vesting Date for any reason other than on account of death, Disability or Retirement (in each case, as defined below),
whether by the Employee or by the Company, and in the latter case whether with or without cause, then the Performance Share Units will be forfeited upon such termination. 

 

	 	(b)	Retirement or Disability. If the Employee’s employment with the Company is terminated prior to the Vesting Date upon Retirement (as defined below) or as the result of a disability under circumstances
entitling the Employee to the commencement of benefits under a long-term disability plan maintained by the Company (“Disability”), then the terms of all outstanding PSUs will be unaffected by such Retirement or Disability and the
PSUs will be paid in accordance with Section 4 above. “Retirement” is defined as termination of employment with the Corporation after reaching age 62 under circumstances that qualify for normal retirement in accordance with the
Martin Marietta Materials, Inc. Pension Plan; provided, that, the Management Development and Compensation Committee of the Board of Directors may in its sole discretion classify an Employee’s termination of employment as Retirement under other
circumstances. 

  

	 	(c)	Death. If, prior to the Vesting Date, the Employee dies while employed by the Company or after termination by reason of Disability, then the terms of all outstanding PSUs will be unaffected by such death and the
PSUs will be paid in accordance with Section 4 above to the Employee’s estate or beneficiary. 

  

	 	(d)	Committee Negative Discretion. The Management Development and Compensation Committee of the Board of Directors may in its sole discretion decide to reduce or eliminate any amount otherwise payable with respect to
an award under Sections 7(b) or 7(c). 

  

	8.	TAX WITHHOLDING 

 At the time PSUs are converted into shares of Common Stock and
delivered to the Employee, the Employee will recognize ordinary income equal to the Fair Market Value of the common shares received. The Company shall withhold applicable taxes as required by law at the time of such Vesting by deducting shares of
Common Stock from the payment to satisfy the obligation prior to the delivery of the certificates for shares of Common Stock. Withholding will be at the minimum rates prescribed by law; therefore, the Employee may owe additional taxes as a result of
the distribution. 

  
 3 

 
The Employee may not request tax to be withheld at greater than the minimum rate. If the Employee terminates employment on account of Disability or Retirement and the PSUs are not forfeited, the
Company may require the Employee to pay to the Company or withhold from the Employee’s compensation, by canceling PSUs or otherwise, an amount equal to satisfy the obligation to withhold federal employment taxes as required by law. 

 

	9.	CHANGE IN CONTROL 

 In the event of a change in control of the Company, as defined in
Section 11 of the Plan, all outstanding PSUs will be deemed non-forfeitable and the Percentage of the Award payable will be the greater of (1) the Percentage as determined by the performance during the Measurement Period up to the day
before the effective date of the change in control, or (2) the target Percentage (100%). The PSUs will be distributed in shares of Common Stock no later than
2 1⁄2 months following the date of such change in control. 
  

	10.	AMENDMENT AND TERMINATION OF PLAN OR AWARDS 

 As provided in Section 8 of the Plan,
subject to certain limitations contained within Section 8, the Board of Directors may at any time amend, suspend or discontinue the Plan and the Management Development and Compensation Committee of the Board of Directors may at any time alter
or amend all Award Agreements under the Plan. Notwithstanding Section 8 of the Plan, no such amendment, suspension or discontinuance of the Plan or alteration or amendment of this Award Agreement shall accelerate any distribution under the Plan
or, except with the Employee’s express written consent, adversely affect any PSU granted under this Award Agreement; provided, however, that the Board of Directors or the Management Development and Compensation Committee may amend the Plan or
this Award Agreement to the extent it deems appropriate to cause this Agreement or the PSUs hereunder to comply with Section 409A (including the distribution requirements thereunder) or be exempt from Section 409A or the tax penalty under
Section 409A(a)(1)(B). If the Plan and the Award Agreement are terminated in a manner consistent with the requirements of Treas. Reg. § 1.409A-3(j)(4)(ix), the Board of Directors may, in its sole discretion, accelerate the conversion of
PSUs to shares of Common Stock and immediately distribute such shares of Common Stock to the Employee. 
  

	11.	EXECUTION OF AWARD AGREEMENT 

 No PSU granted under this Award Agreement is distributable
nor is this Award Agreement enforceable until this Award Agreement has been fully executed by the Company and the Employee. By executing this Award Agreement, the Employee shall be deemed to have accepted and consented to any action taken under the
Plan by the Management Development and Compensation Committee, the Board of Directors or their delegates. 
  

	12.	MISCELLANEOUS 

  

	 	(a)	Nothing contained in the Award Agreement confers on the Employee the rights of a shareholder with respect to this Performance Share Unit award during the Measurement Period. 

 

	 	(b)	For purposes of this Award Agreement, the Employee will be considered to be in the employ of the Company during an approved leave of absence unless otherwise provided in an agreement between the Employee and the
Company. 

  
 4 

	 	(c)	Nothing contained in this Award Agreement or in any Performance Share Unit granted hereunder shall confer upon any Employee any right of continued employment by the Company, expressed or implied, nor limit in any way
the right of the Company to terminate the Employee’s employment at any time. 

  

	 	(d)	Except as provided under Section 6 herein, neither these PSUs nor any of the rights or obligations hereunder shall be assigned or delegated by either party hereto. 

 

	13.	NOTICES 

 Notices and all other communications provided for in this Award Agreement shall
be in writing and shall be deemed to have been duly given when personally delivered or when mailed by overnight mail courier service, postage prepaid, addressed as follows: 

If to the Employee, to the address set forth 

in the first paragraph in this Award Agreement. 

If to the Company, to: 
 Martin
Marietta Materials, Inc. 
 2710 Wycliff Road 

Raleigh, NC 27607 
 Fax:
(919) 783-4535 
 Attn: Corporate Secretary 

or to such other address or such other person as the Employee or the Company shall designate in writing in accordance with this Section 13, except that
notices regarding changes in notices shall be effective only upon receipt. 
  

	14.	GOVERNING LAW 

 This Award Agreement shall be governed by the laws of the State of North
Carolina. 
 IN WITNESS WHEREOF, the Company has caused this Award Agreement to be executed and the Employee has hereunto set his hand as of
the day and year first above written. 
  

			
	MARTIN MARIETTA MATERIALS, INC.
		
	By:		  

			        Corporate Secretary
	
	EMPLOYEE
		
	By:		  

			        Employee’s Signature

  
 5Exhibit 10.15

 Exhibit 10.15 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 

[****] denotes omissions. 

THIRD AMENDMENT 
 TO

 DISCOVERY AND DEVELOPMENT 

COLLABORATION AND LICENSE AGREEMENT 

This Third Amendment to the Discovery and Development Collaboration and License Agreement (the “Third Amendment”) is entered into as
of July 14th, 2014 (the “Third Amendment Effective Date”) by and between Agios Pharmaceuticals, Inc. (“Agios”) and Celgene Corporation (“Celgene”). Agios and Celgene may each be referred to herein individually as a
“Party” and collectively as the “Parties.” Capitalized terms used in this Third Amendment and not otherwise defined herein shall have the meanings set forth in the Agreement. All references to Sections and Articles herein are
references to Sections and Articles of the Agreement. 
 INTRODUCTION 

A. Celgene and Agios are parties to that certain Discovery and Development Collaboration and License Agreement, dated April 14, 2010 and
twice amended on October 3rd, 2011 (the “Agreement”). 
 B. Pursuant to the Agreement, the Parties have engaged in a
collaboration that applies Agios’ expertise and technology to the discovery and validation of novel targets, primarily cancer metabolism targets, and the discovery and development of associated therapeutics, primarily in the Oncology Field, and
provides for the development and commercialization of such therapeutics. 
 C. The Parties wish to amend the Agreement in order to allow
more flexibility in the design and conduct of Phase I MAD Studies, and additional nonclinical and/or clinical activities that Agios agrees to perform at Celgene’s request, by providing for Celgene to pay all Development Costs incurred by Agios
in performing such activities at Celgene’s request and clarifying the mechanism for payment of such Development Costs. 
 NOW,
THEREFORE, in consideration of the covenants and agreements contained herein, and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Agios and Celgene agree as follows: 

1. Amendment of Section 1.48. Section 1.48 is hereby amended and restated in its entirety to read as follows: 

“Development Cost Initiation Date” means (a) with respect to any Co-Commercialized Program for which Celgene exercises
the Celgene Program Option at IND Acceptance, [****]; (b) with respect to any Co-Commercialized Program for which Celgene exercises the Celgene Program Option at Completion of Phase I MAD, [****]; (c) with respect to any Co-Commercialized
Program for which Celgene exercises the Celgene Program Option early under Section 3.6(c), [****]; (d) with respect to a Buy-In Program, [****]; (e) with respect to any Picked Validated Program selected by Celgene, [****]; and
(f) with respect to any Split Program, [****] 

  
 - 1 - 

 2. Amendment of Section 2.4(a). Section 2.4(a) is hereby amended to add
the following to the end of such section: 
 In addition, if Celgene requests that Agios perform any Phase I MAD Study and additional
activities pursuant to Section 3.6(b)(iii)(A)(2) with respect to a Development Candidate, the JDC shall have oversight over such Phase I MAD Study and such additional activities for such Development Candidate (and the related Discovery
Program). 
 3. Amendment of Section 2.8(b). Section 2.8(b) is hereby amended to add Section 3.9(a) to the list
of cross references in such Section 2.8(b), with “3.9(a)” being added between “2.9” and “3.10(e)”. 

4. Amendment and Restatement of Section 3.6(b)(iii)(A)(2). Section 3.6(b)(iii)(A)(2) is hereby amended and restated in
its entirety to read as follows: 
 (2) Celgene, within such Celgene IND Option Exercise Period, may provide Agios written
notice that Celgene elects that Agios conduct the first Phase I MAD Study for the Development Candidate. In such event, Agios shall be responsible for conducting the first Phase I MAD Study with respect to such Development Candidate under a protocol
approved by the JDC by Mutual Consent that meets the Phase I MAD Protocol Criteria, and any additional clinical and/or nonclinical activities that Agios agrees to perform at Celgene’s request, under a Development Plan (and pursuant to a
Development Budget that has been approved by the JDC pursuant to Section 3.9(a)), and, unless the Program becomes a Split Program, Celgene shall be obligated to pay the Phase I Amount and the Development Costs with respect thereto pursuant to
Section 9.4(a)(ii). Upon Agios’ completion of such first Phase I MAD Study, Agios shall deliver to Celgene a final written report that meets the Phase I Report Criteria. Within [****] days of Celgene’s receipt of such written report,
Celgene may reasonably request that Agios provide additional information and access to records (to the extent available to Agios at such time and not yet disclosed to the JRC or JDC as part of the regular updates under Section 3.1 (b) or
3.8(c), or under Section 3.6(b)(ii) or this Section 3.6(b)(iii)) with respect to such Phase I MAD Study and with respect to other Development Candidates that are undergoing IND-Enabling Studies or are at a later stage of Development under
a different Program. Within [****] days following the Completion of Phase I MAD (and any such additional information or access) (such period, as may be so extended, the “Celgene MAD Option Exercise Period”; either the “Celgene
IND Option Exercise Period” or the “Celgene MAD Option Exercise Period” may be referred to as a “Celgene Option Exercise Period”), Celgene may provide Agios written notice of its election to exercise the Celgene Program
Option, in which event the provisions of Section 3.6(b)(iv) shall apply; 

  
 - 2 - 

 5. Amendment and Restatement of Section 3.9(a). Section 3.9(a) is hereby
amended and restated in its entirety to read as follows: 
 (a) The Development under each Co-Commercialized Program, Split
Program, or Buy-In Program shall be governed by a Development Plan (the “Development Plan”) that describes the proposed overall objectives of such Licensed Program, as well as the activities to be performed, the Party responsible for
performance of an activity (which shall be as provided in Section 3.8), [****] budget of Development Costs (“Development Budget”), and anticipated timelines for performance; provided that the Development Budget will only be applicable
for periods following the Development Cost Initiation Date for such Licensed Program. In addition, if Celgene requests that Agios perform any Development activities for a Celgene Picked Validated Program and Agios consents to perform such
activities, or that Agios perform any Phase I MAD Study and additional activities pursuant to Section 3.6(b)(iii)(A)(2), such activities shall also be governed by a Development Plan, with Development Budget; provided that the Development Budget
for any such Phase I MAD Study or additional activities pursuant to Section 3.6(b)(iii)(A)(2) must be approved by the JDC, except that Celgene shall have final decision-making authority with respect to any dispute regarding the Development
Budget for any such Phase I MAD Study and additional activities for Co-Commercialized Programs. 
 6. Amendment of
Section 3.10(b)(ii). Section 3.10(b)(ii) is hereby amended to add the following to the end of such section: 

Notwithstanding the above, in the event a Phase I MAD Study under a Split Program includes a disease-specific expansion cohort, and [****],
that the initial Phase I MAD study and the disease-specific expansion cohort shall support initiation of a subsequent pivotal clinical trial, the principal purpose of which (a) is designed to establish that the product has an acceptable safety
and efficacy profile for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed; and (b) is a registration trial intended to support a filing of
an application for a Regulatory Approval for such compound in the US Territory (the “Pivotal Trial”), then upon the FPD under the Pivotal Trial, Celgene shall pay Agios a milestone payment in an amount equal to the lesser of (A) Ten
Million Dollars (US$10,000,000) or (B) fifty percent (50%) of the costs and expenses for the disease-specific expansion cohort, including the analysis of clinical samples and clinical trial product supply that are actually incurred by or
on behalf of Agios and specifically identifiable or specifically allocable to such disease-specific expansion cohort (the “Disease-Specific Expansion Cohort Milestone Payment”). Such Disease-Specific Expansion Cohort Milestone Payment
shall be made within [****] days after Celgene’s receipt of appropriate invoice. Unless otherwise agreed by the JDC by Mutual Consent, the maximum amount of Disease-Specific Expansion Cohort Milestone Payments payable under a Split Program will
be Ten Million Dollars (US$10,000,000), regardless of the number of disease-specific expansion cohorts and Pivotal Trials under the Split Program. 

  
 - 3 - 

 In the event a Phase I MAD Study under a Split Program already includes a disease- specific
expansion cohort, and the JDC by Mutual Consent agrees to amend the Phase I MAD Study to include a Phase II Study arm with a larger patient population in the same disease-specific indication, then the Development Cost Initiation Date shall begin
upon [****]. 
 7. Amendment of Section 4.1(h). Section 4.1(h) is hereby amended to append the following phrase at
the end of the sentence: except to the extent such Manufacturing Costs are included in Development Costs payable by Celgene pursuant to Section 9.4(a)(ii) in connection with a Phase I MAD Study or additional activities performed by Agios
pursuant to Section 3.6(b)(iii)(A)(2)”. 
 8. Amendment and Restatement of Section 9.3(a). Section 9.3(a)
is hereby amended and restated in its entirety to read as follows: 
 (a) Payments for Co-Commercialized Programs. Following
Celgene’s selection of a Development Candidate at the DC Selection Stage under a Co- Commercialized Program pursuant to Section 3.6(b), on a Program-by-Program basis, Celgene shall pay Agios Twenty-Two Million Five Hundred Thousand Dollars
(US$22,500,000) (the “IND Amount”) upon an IND Acceptance achieved by Agios for such Development Candidate in such Co-Commercialized Program pursuant to Section 3.6(b)(iii)(A); provided that (i) no such IND Amount will be due
with respect to the first [****] IND Acceptances achieved by Agios under Co-Commercialized Programs for which IND Acceptance is achieved; (ii) no such IND Amount will be due prior to [****]; and (iii) no such IND Amount will be due
with respect to any IND Acceptance achieved by Agios under an Optionable Program that becomes a Split Program pursuant to Section 3.10. For clarity, Celgene shall not owe the IND Amount with respect to any Picked Validated Program selected by
Celgene or for any Buy-In Program (whether Celgene is the Buy-In Party or Agios is). 
 9. Amendment and Restatement of
Section 9.4(a). Section 9.4(a) is hereby amended and restated in its entirety to read as follows: 
 (a)
For Licensed Programs; Phase I MAD Study. Except as set forth in clauses (b) and (c) below with respect to Split Programs and Buy-In Programs, the following shall apply for Co-Commercialized Programs and Celgene Picked Validated Programs
and for any Phase I MAD Study pursuant to Section 3.6(b)(iii)(A)(2): 
 (i) With respect to each Co-Commercialized
Program and Picked Validated Program selected by Celgene under which Agios performs Development activities hereunder, Celgene shall be responsible for bearing one hundred percent (100%) of the Development Costs for such Licensed Program,
including the Development Costs of any Clinical Trials or other Licensed Program activities conducted by Agios (at Celgene’s request pursuant to Section 3.6(b)(iv)(B) and as agreed to by Agios), that (A) are incurred after the
Development Cost Initiation Date for such Program and (B) are within [****] percent ([****]%) of the approved Development Budget 

  
 - 4 - 

 
under the Development Plan for such Program. Notwithstanding anything herein to the contrary, any costs of the first Phase I MAD Study conducted by Agios, pursuant to
Section 3.6(b)(iii)(A)(2)), shall not be included in the Development Costs under this Section 9.4(a)(i) but shall be addressed by Section 9.4(a)(ii). 

(ii) If Celgene requests that Agios perform the first Phase I MAD Study and any additional activities pursuant to
Section 3.6(b)(iii)(A)(2), unless the applicable Program becomes a Split Program, then upon the earlier of (I) determination of the first maximum tolerated dose for the Development Candidate by Agios (the “MTD Determination”) or
(II) the Option Exercise Date, Celgene shall pay Agios a milestone payment in an amount equal to the greater of (1) Five Million Dollars (US$5,000,000) or (2) one hundred percent (100%) of the Development Costs for such Phase I MAD
Study conducted by Agios that (A) are incurred for any such Phase I MAD Study up to the earlier of the MTD Determination or the Option Exercise Date and (B) are within [****] percent ([****]%) of the approved Development Budget under
the Development Plan for such Phase I MAD Study (the “Phase I Amount”). The Phase I Amount shall be payable within [****] days following the earlier of Celgene’s receipt of a written notice of the MTD Determination or the Option
Exercise Date. Subsequent to the earlier of the MTD Determination or the Option Exercise Date, Celgene shall be responsible for bearing one hundred percent (100%) of the Development Costs for remaining phase(s) of such Phase I MAD Study that
(A) are incurred for any such Phase I MAD Study and (B) are within [****] percent ([****]%) of the approved Development Budget under the Development Plan for such Phase I MAD Study. For clarity, Celgene shall not be responsible for
the Phase I Amount or the Development Costs of any Phase I MAD Study conducted by Agios, pursuant to Section 3.6(b)(iii)(A)(2)), with respect to any Split Program. 

(iii) Within [****] days following the beginning of the [****] of each [****], Agios shall prepare and deliver to Celgene
a [****] report detailing its Development Costs incurred during the [****] of such [****] and detailing a budget estimate (“Budget Estimate”) for the remaining [****] of such [****], with respect to which Celgene is required to pay
pursuant to Section 9.4(a)(i) or (ii). Agios shall submit any supporting information reasonably requested by Celgene related to such Development Costs included in Agios’ report within [****] days after Agios’ receipt of such
request. Celgene shall pay all amounts of such Development Costs within [****] days following the later of Celgene’s receipt of such report and Celgene’s receipt of such supporting information. Within [****] days following the
end of each [****], Agios shall prepare and deliver to Celgene a reconciliation report detailing the difference between its Development Costs incurred during the [****] of such [****], with respect to which Celgene is required to pay pursuant to
Section 9.4(a)(i) or (ii), and the Budget Estimate for the same period. Agios shall submit any supporting information reasonably requested by Celgene related to such Development Costs included in Agios’ reconciliation report within
[****] days after Agios’ receipt of such request. Celgene shall pay any unpaid amounts of any Development Costs identified in such reconciliation report within [****] days following the later of Celgene’s receipt of such
reconciliation report and Celgene’s receipt of such supporting 

  
 - 5 - 

 
information associated therewith. Any overpayment identified in such reconciliation report shall be credited towards the payment obligations of Celgene pursuant to Section 9.4(a)(i) or
(ii) for the following Calendar Quarter. 
 10. Additional Conforming Amendments. 

(a) Section 1.130 is hereby amended to replace the table row for “Phase I Amount” with the following: 

“Phase I Amount            9.4(a)(ii)”. 

(b) Each reference in the Agreement to Section 9.3(a)(i) is hereby replaced with a reference to Section 9.3(a). 

(c) Section 1.41 is hereby amended to replace the reference to Section 9.4(a)(ii) with a reference to
Section 9.4(a)(iii). 
 11. Incorporation. Article XV is hereby incorporated mutatis mutandis into this Third
Amendment 
 12. Effect on Agreement. Except as specifically amended by this Third Amendment, the Agreement will remain in
full force and effect and is hereby ratified and confirmed. To the extent a conflict arises between the terms of the Agreement and this Third Amendment, the terms of this Third Amendment shall prevail but only to the extent necessary to accomplish
their intended purpose. 
 [Remainder of Page Intentionally Left Blank] 

  
 - 6 - 

 IN WITNESS WHEREOF, the Parties have executed this Third Amendment as of the Third Amendment
Effective Date. 
  

			
	AGIOS PHARMACEUTICALS, INC.
		
	By:		 /s/ David P. Schenkein

	Title:		 CEO

	
	CELGENE CORPORATION
		
	By:		 /s/ Thomas O. Daniel

	Title:		 President R & ED

  

			
	Celgene Legal:		/s/ JMC

  
 - 7 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]